Inactive Instrument

Highlights Medical Prognosis Institute A/S Nasdaq Copenhagen

Equities

MPIT

DK0060732477

Highlights

Unlock all the news: Be the first to know and act before the market!

Allarity Therapeutics, Inc.' Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer	06-25	CI
Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial	05-24	CI
Allarity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Allarity Therapeutics Says Stockholders' Equity 'Significantly' Exceeds Nasdaq's $2.5 Million Minimum Rule	05-06	MT
Allarity Therapeutics, Inc. Announces Early Discontinuation of Its Phase 2 Clinical Trial of Stenoparib	05-02	CI
Top Premarket Gainers	04-12	MT
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer	03-27	CI
Allarity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-08	CI
Allarity Therapeutics, Inc. Announces Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP Companion Diagnostic	12-05	CI
Allarity Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Allarity Therapeutics Announces Positive Early Data from an Ongoing Clinical Trial, and External Partnering for Its DRP Technology	23-09-14	CI
Allarity Therapeutics, Inc. Announces the Publication of its Clinical Validation of a Novel Drug-Specific DRP-Companion Diagnostic for Dovitinib in the Peer-Reviewed Journal PLOS ONE	23-08-30	CI
Allarity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Allarity Therapeutics, Inc. and Detsamma Investments Pty. Ltd. Announce Collaboration to Support Clinical Development of Deflexifol? with DRP® Companion Diagnostics	23-07-31	CI
Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol with DRP Companion Diagnostics	23-07-31	CI
Allarity Therapeutics, Inc. Announces Initial Results from Its European Phase 2 Clinical Trial Evaluating the Efficacy of IxempraÂ®? in Metastatic Breast Cancer Patients	23-07-05	CI
Allarity Therapeutics, Inc. Announces Results of Prospective Phase 2 Clinical Study	23-05-30	CI
Allarity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Allarity Therapeutics, Inc. Accelerates Trial Enrollment to Bring Fda-Approves Breast Cancer Treatment to European Market - Interim Results Could Be Released in Second Half of 2023	23-04-27	CI
Allarity Therapeutics Doses Its First Patient in Phase 1B of Its Clinical Trial for the Novel Combination Therapy of Two Drugs, Stenoparib and Dovitinib	23-04-17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Medical Prognosis Institute A/S Nasdaq Copenhagen

Equities

MPIT

DK0060732477

Highlights

Filters